Colon Pharmaceuticals announced that a new application for marketing of TROP2ADC lukansastuzumab, the core product of the company's holding subsidiary, was accepted by the State Drug Administration for first-line treatment of PD-L1TPS < 1% negative EGFR mutation and ALK negative adult patients with locally advanced or metastatic non-squamous non-small cell lung cancer with Pabolizumab. This application is the seventh application for marketing of lucansastuzumab accepted. Based on the positive results of the Phase 3 OptiTrop-Lung06 study, the combination therapy showed significant improvements in statistics and clinical significance in terms of progression-free survival. Up to now, the product has been approved for marketing in China for 4 indications, 2 of which are covered by medical insurance.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.